Terms: = Breast cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Clinical Outcome
4 results:
1. Endogenous Signaling Molecule Activating (ESMA) cars: A Novel car Design Showing a Favorable Risk to Potency Ratio for the Treatment of Triple Negative breast cancer.
Ebbinghaus M; Wittich K; Bancher B; Lebedeva V; Appelshoffer A; Femel J; Helm MS; Kollet J; Hardt O; Pfeifer R
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203786
[TBL] [Abstract] [Full Text] [Related]
2. Homogeneously high expression of CD32b makes it a potential target for car-T therapy for chronic lymphocytic leukemia.
Wang G; Sun X; Zuo S; Li C; Niu Q; Xia Y; Meng Y; Liu M; Fang Z; Yang X; Jiang Y; Wang S; Cui H; Huang H; Jiang E; Zhou D; Deng Q; Pan J; Feng X
J Hematol Oncol; 2021 Sep; 14(1):149. PubMed ID: 34530888
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer.
Nelson MA; Ngamcherdtrakul W; Luoh SW; Yantasee W
Cancer Metastasis Rev; 2021 Jun; 40(2):519-536. PubMed ID: 33963482
[TBL] [Abstract] [Full Text] [Related]
4. PKA signaling drives mammary tumorigenesis through Src.
Beristain AG; Molyneux SD; Joshi PA; Pomroy NC; Di Grappa MA; Chang MC; Kirschner LS; Privé GG; Pujana MA; Khokha R
Oncogene; 2015 Feb; 34(9):1160-73. PubMed ID: 24662820
[TBL] [Abstract] [Full Text] [Related]
